Pfizer’s vaccine could be distributed this year in the United States and Europe (REUTERS / Dado Ruvic)
BioNTech co-founder, Ugur Sahin, confirmed this Thursday that the coronavirus vaccine that his German company is developing with Pfizer it could be released before the end of the year in the United States or Europe.
“We are working at full speed”he told . in an interview with Zoom, confirming that the companies plan to request authorization for the emergency use of their jab in the United States on Friday, while European regulators will receive another batch of data “next week.”
“There is a possibility that we may still receive approval from the United States or Europe or both regions this year,” Sahin said. And I add: “We can even start delivering the vaccine in December,” he added, “if everyone works very closely together.”
In a joint statement issued Wednesday, the companies said the vaccine is 95% effective in preventing COVID-19, compared to the 90% announced last week, based on the final full results of their large-scale clinical trial. phase scale 3.
US drugmaker Pfizer and its German partner BioNTech said the product will be submitted for regulatory approval “in a few days,” after their final analysis suggested that the drug is even more effective than previously thought. The results also showed that the vaccine protects older people with a higher risk of dying from coronavirus.
BioNTech Co-Founder Ugur Sahin (REUTERS / Fabian Bimmer)
“The results of the study mark an important step in this historic eight-month journey to present a vaccine capable of helping end this devastating pandemic,” said Pfizer CEO, Albert Bourla.
Pfizer had initially estimated that its vaccine was more than 90% effective after 94 infections were counted. With Wednesday’s announcement, the company has racked up 170 infections in the study, saying only eight of them occurred in volunteers who received the actual vaccine rather than a placebo. One of those eight developed a serious illness, the company said.
Pfizer says that you now have the vaccine safety data you need to request authorization of the Food and Drug Administration of the United States.
The company did not disclose security details, but said that no serious side effects have been reported from the vaccineThe most common problem is fatigue after the second dose of the vaccine, which affects approximately 4% of the participants.
Pfizer and BioNTech expect to produce up to 50 million doses of vaccines globally by 2020 (Pfizer / delivery via .)
The study has enrolled nearly 44,000 people in the United States and five other countries. The trial will continue to collect safety and efficacy data in volunteers for a further two years.
Pfizer and BioNTech anticipated that they expect to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion doses in 2021.
Oxford published the final report of Phase 2 of its vaccine: it is safe in older adults and generates an immune response
Dealing With People Who Ignore Safety Around COVID-19
WHO supported keeping schools open, calling lockdowns a “waste of resources”